According to the statistics in this study, MSLN was present in 15 of 48 (31%) lung cancers (adenocarcinomas (12/31) and squamous carcinomas (limited, 3/17)) and in 42 of 86 (49%) nonpulmonary adenocarcinomas (ovary (14/14), peritoneum (5/5), endometrium (6/9), pancreas (10/11), stomach (2/4), and colon (5/16); none of 12 breast, 9 kidney, 4 thyroid, and 2 prostate cancers showed evidence of MSLN) according to assays with the 5B2 anti-MSLN monoclonal antibody. This evidence concerns the gene MSLN and lung cancer.